Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity.

Autor: Zhang X; The Wistar Institute, Philadelphia, PA, USA. xzhan325@jh.edu.; Ludwig Institute for Cancer Research, New York, NY, USA. xzhan325@jh.edu.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. xzhan325@jh.edu., Pant SM; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.; Department of Systems Biology, Harvard Medical School, Boston, MA, USA., Ritch CC; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Tang HY; The Wistar Institute, Philadelphia, PA, USA., Shao H; The Wistar Institute, Philadelphia, PA, USA., Dweep H; The Wistar Institute, Philadelphia, PA, USA., Gong YY; The Wistar Institute, Philadelphia, PA, USA.; Ludwig Institute for Cancer Research, New York, NY, USA., Brooks R; The Wistar Institute, Philadelphia, PA, USA.; Ludwig Institute for Cancer Research, New York, NY, USA., Brafford P; The Wistar Institute, Philadelphia, PA, USA.; Ludwig Institute for Cancer Research, New York, NY, USA., Wolpaw AJ; The Wistar Institute, Philadelphia, PA, USA.; Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.; Center for Childhood Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Lee Y; Department of Translational Medicine and Physiology, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA., Weeraratna A; Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA., Sehgal A; Howard Hughes Medical Institute, Chronobiology and Sleep Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Herlyn M; The Wistar Institute, Philadelphia, PA, USA., Kossenkov A; The Wistar Institute, Philadelphia, PA, USA., Speicher D; The Wistar Institute, Philadelphia, PA, USA., Sorger PK; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.; Department of Systems Biology, Harvard Medical School, Boston, MA, USA., Santagata S; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.; Department of Systems Biology, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Dang CV; The Wistar Institute, Philadelphia, PA, USA. cvdang@jhmi.edu.; Ludwig Institute for Cancer Research, New York, NY, USA. cvdang@jhmi.edu.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. cvdang@jhmi.edu.; Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. cvdang@jhmi.edu.

Publikováno v: Nature communications [Nat Commun] 2024 Jan 20; Vol. 15 (1), pp. 633. Date of Electronic Publication: 2024 Jan 20.

Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin.

Autor: Tervonen TA; Research Programs Unit/Translational Cancer Medicine and Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Pant SM; Research Programs Unit/Translational Cancer Medicine and Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Belitškin D; Research Programs Unit/Translational Cancer Medicine and Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Englund JI; Research Programs Unit/Translational Cancer Medicine and Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Närhi K; Research Programs Unit/Translational Cancer Medicine and Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland., Haglund C; Research Programs Unit/Translational Cancer Medicine Research Program and Department of Surgery, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Kovanen PE; Research Programs Unit/Translational Cancer Medicine and Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland., Verschuren EW; Research Programs Unit/Translational Cancer Medicine and Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland., Klefström J; Research Programs Unit/Translational Cancer Medicine and Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland. juha.klefstrom@helsinki.fi.; Finnish Cancer Institute, FICAN South, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Publikováno v: Cancer research [Cancer Res] 2021 Mar 15; Vol. 81 (6), pp. 1513-1527. Date of Electronic Publication: 2021 Jan 18.

Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform.

Autor: Pant SM; Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology & Medicum, University of Helsinki , P.O. Box 63, Haartmaninkatu 8 , 00014 Helsinki , Finland., Mukonoweshuro A; Cyclofluidic Ltd. , Biopark, Broadwater Road , Welwyn Garden City , AL7 3AX , U.K., Desai B; Cyclofluidic Ltd. , Biopark, Broadwater Road , Welwyn Garden City , AL7 3AX , U.K., Ramjee MK; Cyclofluidic Ltd. , Biopark, Broadwater Road , Welwyn Garden City , AL7 3AX , U.K., Selway CN; Cyclofluidic Ltd. , Biopark, Broadwater Road , Welwyn Garden City , AL7 3AX , U.K., Tarver GJ; Cyclofluidic Ltd. , Biopark, Broadwater Road , Welwyn Garden City , AL7 3AX , U.K., Wright AG; Cyclofluidic Ltd. , Biopark, Broadwater Road , Welwyn Garden City , AL7 3AX , U.K., Birchall K; LifeArc , Accelerator Building, Open Innovation Campus , Stevenage , SG1 2FX , U.K., Chapman TM; LifeArc , Accelerator Building, Open Innovation Campus , Stevenage , SG1 2FX , U.K., Tervonen TA; Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology & Medicum, University of Helsinki , P.O. Box 63, Haartmaninkatu 8 , 00014 Helsinki , Finland., Klefström J; Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology & Medicum, University of Helsinki , P.O. Box 63, Haartmaninkatu 8 , 00014 Helsinki , Finland.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2018 May 24; Vol. 61 (10), pp. 4335-4347. Date of Electronic Publication: 2018 May 14.

Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.

Autor: Tervonen TA; Cancer Cell Circuitry Laboratory, Research Programs Unit, Translational Cancer Biology and Institute of Biomedicine, University of Helsinki, Helsinki, Finland., Belitškin D; Cancer Cell Circuitry Laboratory, Research Programs Unit, Translational Cancer Biology and Institute of Biomedicine, University of Helsinki, Helsinki, Finland., Pant SM; Cancer Cell Circuitry Laboratory, Research Programs Unit, Translational Cancer Biology and Institute of Biomedicine, University of Helsinki, Helsinki, Finland., Englund JI; Cancer Cell Circuitry Laboratory, Research Programs Unit, Translational Cancer Biology and Institute of Biomedicine, University of Helsinki, Helsinki, Finland., Marques E; Cancer Cell Circuitry Laboratory, Research Programs Unit, Translational Cancer Biology and Institute of Biomedicine, University of Helsinki, Helsinki, Finland., Ala-Hongisto H; Cancer Cell Circuitry Laboratory, Research Programs Unit, Translational Cancer Biology and Institute of Biomedicine, University of Helsinki, Helsinki, Finland., Nevalaita L; Cancer Cell Circuitry Laboratory, Research Programs Unit, Translational Cancer Biology and Institute of Biomedicine, University of Helsinki, Helsinki, Finland., Sihto H; Department of Oncology, University of Helsinki & Helsinki University Central Hospital, Helsinki, Finland., Heikkilä P; Department of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland., Leidenius M; Breast Surgery Unit, Helsinki University Central Hospital, Helsinki, Finland., Hewitson K; Helsinki Innovation Services Ltd, Tukholmankatu 8A, 00290, University of Helsinki, Helsinki, Finland., Ramachandra M; Aurigene Discovery Technologies Limited, 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore, India., Moilanen A; Orion Corporation, Orion Pharma, Turku, Finland., Joensuu H; Department of Oncology, University of Helsinki & Helsinki University Central Hospital, Helsinki, Finland., Kovanen PE; Department of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland., Poso A; School of Pharmacy, University of Eastern Finland, Kuopio, Finland and Finnish Institute of Molecular Medicine, Helsinki, Finland., Klefström J; Cancer Cell Circuitry Laboratory, Research Programs Unit, Translational Cancer Biology and Institute of Biomedicine, University of Helsinki, Helsinki, Finland.

Publikováno v: Oncogene [Oncogene] 2016 Apr 07; Vol. 35 (14), pp. 1832-46. Date of Electronic Publication: 2015 Jul 13.